Lanying Qin

Cangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Prospective Evaluation of Cross-linked Sodium Hyaluronate Gel for Injection in Treating Moderate-to-Severe Nasolabial Folds: A Randomized Controlled Evaluator-Blind Non-inferiority Study.

Prospective Evaluation of Cross-linked Sodium Hyaluronate Gel for Injection in Treating Moderate-to-Severe Nasolabial Folds: A Randomized Controlled Evaluator-Blind Non-inferiority Study.

Journal: Dermatology and therapy

Published: April 10, 2026

SSGJ-608 in moderate-to-severe plaque psoriasis: a multicenter, randomized, open-label, phase 3 study.

SSGJ-608 in moderate-to-severe plaque psoriasis: a multicenter, randomized, open-label, phase 3 study.

Journal: Frontiers in immunology

Published: February 13, 2026

A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis.

A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis.

Journal: Journal of the American Academy of Dermatology

Published: February 11, 2026

Primary familial and congenital polycythemia caused by EPOR gene mutation: two cases report and literature review

Primary familial and congenital polycythemia caused by EPOR gene mutation: two cases report and literature review

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: December 17, 2025

Efficacy and Safety of Switching to Picankibart from Non-interleukin-23 Subunit p19 Inhibitors in Patients with Plaque Psoriasis: A Multicenter, Open-Label, Phase 2 Trial.

Efficacy and Safety of Switching to Picankibart from Non-interleukin-23 Subunit p19 Inhibitors in Patients with Plaque Psoriasis: A Multicenter, Open-Label, Phase 2 Trial.

Journal: Advances in therapy

Published: September 04, 2025

Superior efficacy and comparable safety of calcipotriol plus betamethasone dipropionate foam vs. ointment in Chinese patients with plaque psoriasis: A randomized phase 3 trial.

Superior efficacy and comparable safety of calcipotriol plus betamethasone dipropionate foam vs. ointment in Chinese patients with plaque psoriasis: A randomized phase 3 trial.

Journal: Chinese medical journal

Published: March 21, 2025

Efficacy and Safety of Crisugabalin (HSK16149) in Adults with Postherpetic Neuralgia: A Phase 3 Randomized Clinical Trial.

Efficacy and Safety of Crisugabalin (HSK16149) in Adults with Postherpetic Neuralgia: A Phase 3 Randomized Clinical Trial.

Journal: JAMA dermatology

Published: September 25, 2024

A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis.

A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis.

Journal: The British journal of dermatology

Published: September 26, 2023

Expression of Serum Anti-BP180/230 Antibodies in Bullous Pemphigoid Patients Combined with Nervous System Diseases and Relevant Factor Analysis.

Expression of Serum Anti-BP180/230 Antibodies in Bullous Pemphigoid Patients Combined with Nervous System Diseases and Relevant Factor Analysis.

Journal: Journal of the College of Physicians and Surgeons--Pakistan : JCPSP

Published: February 14, 2023

Identity-by-Descent Analysis Reveals Susceptibility Loci for Severe Acne in Chinese Han Cohort.

Identity-by-Descent Analysis Reveals Susceptibility Loci for Severe Acne in Chinese Han Cohort.

Journal: The Journal of investigative dermatology

Published: December 01, 2017

Showing 1-10 of 10

Last Updated: 09/26/2026